A citation-based method for searching scientific literature

E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, K Kotsa. Endocrinol Diabetes Metab Case Rep 2016
Times Cited: 21







List of co-cited articles
192 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
17
58

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
74
42

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
87
33

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
33

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
41
33

Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA).
R Buzzetti, P Pozzilli, R Frederich, N Iqbal, B Hirshberg. Diabetes Metab Res Rev 2016
31
33

Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudete Justina Valduga, Cristina Eunice Okuyama, Renata Gorjão, Regina Mara Silva Pereira, Susana Nogueira Diniz. Eur J Pharm Sci 2017
40
33


Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.
Narayanan Kandasamy, Graham Lennox, Anand K Annamalai, Gerald Maguire, Amanda I Adler. Endocr Pract 2012
9
66

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin.
Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble, Constantin Polychronakos. Endocrinol Diabetes Metab Case Rep 2014
14
42

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Noriko Satoh-Asahara, Yousuke Sasaki, Hiromichi Wada, Mayu Tochiya, Azusa Iguchi, Reiko Nakagawachi, Shinji Odori, Shigeo Kono, Koji Hasegawa, Akira Shimatsu. Metabolism 2013
127
28

Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).
Xia Li, Lan Liao, Xiang Yan, Gan Huang, Jian Lin, Minxiang Lei, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2009
69
23

Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
Bertram Bengsch, Bianca Seigel, Tobias Flecken, Julia Wolanski, Hubert E Blum, Robert Thimme. J Immunol 2012
103
23


Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.
Shelley Lindley, Colin M Dayan, Amanda Bishop, Bart O Roep, Mark Peakman, Timothy I M Tree. Diabetes 2005
595
23


Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
68
23

Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study.
Zhiguang Zhou, Yufei Xiang, Linong Ji, Weiping Jia, Guang Ning, Gan Huang, Lin Yang, Jian Lin, Zhenqi Liu, William A Hagopian,[...]. Diabetes 2013
138
23

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
37
23

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
25
23

Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
174
23

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
39
19

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
19




Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.
Núria Alonso, María Teresa Julián, Jorge Carrascal, Roger Colobran, Irma Pujol-Autonell, Silvia Rodriguez-Fernández, Aina Teniente, Marco Antonio Fernández, Antoni Miñarro, María Carmen Ruiz de Villa,[...]. PLoS One 2015
7
57

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
182
19

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Payal Shah, Amin Ardestani, Gitanjali Dharmadhikari, Svenja Laue, Desiree M Schumann, Julie Kerr-Conte, Francois Pattou, Thomas Klein, Kathrin Maedler. J Clin Endocrinol Metab 2013
65
19



Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study.
E Hyppönen, E Läärä, A Reunanen, M R Järvelin, S M Virtanen. Lancet 2001
19

Latent autoimmune diabetes in adults (LADA) should be less latent.
S Fourlanos, F Dotta, C J Greenbaum, J P Palmer, O Rolandsson, P G Colman, L C Harrison. Diabetologia 2005
202
19


Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes.
Yoshimasa Aso, Maiko Fukushima, Masaaki Sagara, Teruo Jojima, Toshie Iijima, Kunihiro Suzuki, Atsushi Momobayashi, Kikuo Kasai, Toshihiko Inukai. Diabetes Res Clin Pract 2015
23
14


Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.
Tímea Varga, Anikó Somogyi, Gábor Barna, Barna Wichmann, Géza Nagy, Károly Rácz, László Selmeci, Gábor Firneisz. Pathol Oncol Res 2011
39
14

GIP and GLP-1, the two incretin hormones: Similarities and differences.
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe. J Diabetes Investig 2010
280
14

Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
14

No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes.
Markus Walter, Thomas Kaupper, Kerstin Adler, Johannes Foersch, Ezio Bonifacio, Anette-G Ziegler. Diabetes Care 2010
79
14

Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation.
Sheng Chen, Gary P Sims, Xiao Xiang Chen, Yue Ying Gu, Shunle Chen, Peter E Lipsky. J Immunol 2007
633
14

Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: An experimental study.
Urmila Anil Kagal, Netravathi Basavaraj Angadi, Somnath Mallikarjun Matule. Int J Appl Basic Med Res 2017
14
21

Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential.
Wendy Dankers, Edgar M Colin, Jan Piet van Hamburg, Erik Lubberts. Front Immunol 2017
154
14

No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.
Carla Bizzarri, Dario Pitocco, Nicola Napoli, Enrico Di Stasio, Daria Maggi, Silvia Manfrini, Concetta Suraci, Maria Gisella Cavallo, Marco Cappa, Giovanni Ghirlanda,[...]. Diabetes Care 2010
80
14

Negativation of type 1 diabetes-associated autoantibodies to glutamic acid decarboxylase and insulin in children treated with oral calcitriol.
Dimitrios T Papadimitriou, Chrisanthi Marakaki, Andreas Fretzayas, Polyxeni Nicolaidou, Anastasios Papadimitriou. J Diabetes 2013
14
21

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
A D Dobrian, Q Ma, J W Lindsay, K A Leone, K Ma, J Coben, E V Galkina, J L Nadler. Am J Physiol Endocrinol Metab 2011
108
14


A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes.
Asal Ataie-Jafari, Seng-Cheong Loke, Asmah B Rahmat, Bagher Larijani, Farzaneh Abbasi, Melvin K S Leow, Zaitun Yassin. Clin Nutr 2013
26
14

Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial.
Gerlies Treiber, Barbara Prietl, Elke Fröhlich-Reiterer, Evelyne Lechner, Anja Ribitsch, Maria Fritsch, Birgit Rami-Merhar, Claudia Steigleder-Schweiger, Winfried Graninger, Martin Borkenstein,[...]. Clin Immunol 2015
41
14



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.